Soliman 2009.

Methods	Open label, parallel‐group RCT
Participants	216 participants (105 polypill; 111 comparator); ≥ 40 years for men and ≥ 50 years for women; estimated 10‐year World Health Organization total cardiovascular risk score ≥ 20% without established cardiovascular disease
Interventions	Intervention: Red Heart pill 2b (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) Comparator: standard practice defined by the study investigators
Outcomes	SBP, total cholesterol, 10‐year cardiovascular disease risk, adherence, fasting glucose, creatinine, potassium, and liver enzymes
Notes	Comparator: inactive/usual care
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No method of randomisation stated
Allocation concealment (selection bias)	Unclear risk	No method of randomisation stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear how missing data were handled
Selective reporting (reporting bias)	Low risk	Primary outcomes (blood pressure, cholesterol, ten year CVD risk) all reported
Other bias	High risk	Use of non‐study antihypertensives and statins very different between centres